News

Show
news from

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress

Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK

Load more

Search